Sarsia

Heimdall Power AS, established in Bergen, Norway in 2015, specializes in developing innovative sensor platforms for power grids. Their flagship product, Neuron, monitors transmission lines and distribution feeders in real-time, providing situational awareness through features such as line monitoring, fault detection, dynamic line rating, and advanced analytics. By installing these sensors on power lines to collect data on parameters like temperature, load, and line sag, Heimdall Power enables grid owners to optimize operations, enhance reliability, facilitate the transition to renewable energy sources, and ultimately improve overall grid performance.

Cetasol is an innovative technology firm focusing on intelligent solutions for sustainability in marine sector. It helps in decision-making, timesaving, emission reduction, and more. They provide solutions to enhance maritime operations and services for consultant improvements.

Calluna Pharma is a clinical-stage company developing selective antibody therapies targeting immunological diseases. Its pipeline includes novel candidates addressing unmet clinical needs.

Heimdall Power AS, established in Bergen, Norway in 2015, specializes in developing innovative sensor platforms for power grids. Their flagship product, Neuron, monitors transmission lines and distribution feeders in real-time, providing situational awareness through features such as line monitoring, fault detection, dynamic line rating, and advanced analytics. By installing these sensors on power lines to collect data on parameters like temperature, load, and line sag, Heimdall Power enables grid owners to optimize operations, enhance reliability, facilitate the transition to renewable energy sources, and ultimately improve overall grid performance.

Sonoclear AS, founded in 2016 and based in Trondheim, Norway, specializes in the manufacturing of SonoClear®, an acoustic coupling fluid designed for brain tumor surgery. This innovative product enhances ultrasound imaging by eliminating image artifacts that typically occur in resection cavities. By improving the clarity of surgical images, SonoClear® supports healthcare professionals in making informed clinical decisions during procedures. The company is focused on advancing surgical techniques and outcomes in the field of neurosurgery through its specialized technology.

BerGenBio is a clinical-stage biotechnology company focused on developing novel therapies targeting aggressive cancers. Its lead drug candidate, bemcentinib (BGB324), is an oral small molecule inhibitor of AXL receptor tyrosine kinase, currently in clinical development for various cancer indications.

APIM Therapeutics develops innovative peptide drugs targeting Proliferating Cell Nuclear Antigen (PCNA), a key protein regulating cellular responses to DNA damage and stress in cancer cells. Founded on groundbreaking research from NTNU, Trondheim, Norway, the company aims to eliminate and cure cancer-specific tumor cells.

BerGenBio is a clinical-stage biotechnology company focused on developing novel therapies targeting aggressive cancers. Its lead drug candidate, bemcentinib (BGB324), is an oral small molecule inhibitor of AXL receptor tyrosine kinase, currently in clinical development for various cancer indications.

APIM Therapeutics develops innovative peptide drugs targeting Proliferating Cell Nuclear Antigen (PCNA), a key protein regulating cellular responses to DNA damage and stress in cancer cells. Founded on groundbreaking research from NTNU, Trondheim, Norway, the company aims to eliminate and cure cancer-specific tumor cells.

BerGenBio is a clinical-stage biotechnology company focused on developing novel therapies targeting aggressive cancers. Its lead drug candidate, bemcentinib (BGB324), is an oral small molecule inhibitor of AXL receptor tyrosine kinase, currently in clinical development for various cancer indications.

Isentio, established in 2014 and headquartered in Santa Cruz, California, specializes in developing and providing cloud-based SaaS solutions for infection intelligence. Its flagship product, RipSeq, significantly enhances the bacterial identification process by leveraging advanced DNA analysis methods. RipSeq is an online software tool designed to quickly identify bacteria in clinical samples, even when multiple bacteria are present, thereby reducing the time from sample to report by days.

Avexxin's therapeutic approach is built on more than a decade of research into the biological mechanisms involved in inflammatory diseases at the Norwegian University of Science and Technology. Avexxin's goal is to create a therapeutic company based on the discovery and development of novel therapeutics that address the fundamental mechanisms involved in inflammatory diseases.

WindSim AS is a company based in Tonsberg, Norway, specializing in software for simulating wind resources in complex terrains. It offers a product known as WindSim, which optimizes energy production from wind turbines across Europe, Asia, Australia, and North America. The software leverages advanced computational fluid dynamics and automated deep neural learning technologies to enhance the efficiency of energy projects by accurately forecasting energy production. In addition to its software solutions, WindSim provides consulting and training services to help clients effectively utilize its products. The company's offerings are distributed in various countries, including China, France, Germany, Italy, Spain, and Taiwan. WindSim AS was previously named VECTOR AS before adopting its current name in December 2005.